Hovione executives Jean-Luc Herbeaux and Guy Villax stand in front of their booth at CPhI in Milan (Hovione PR)

Af­ter 25 years, Hov­ione's CEO will step down; Helsinn gains in­fi­gra­tinib li­cense from Bridge­Bio 

Hov­ione’s cur­rent COO will be­come its CEO on April 1.

The com­pa­ny an­nounced that Guy Vil­lax, the CEO for 25 years, will step down from his role. He will tran­si­tion to the role of board mem­ber and share­hold­er. The com­pa­ny grew 10-fold in his tenure, grow­ing to 2,000 team mem­bers and four pro­duc­tion sites in the US, Chi­na, Por­tu­gal and Ire­land.

“It has been a priv­i­lege and hon­or to lead Hov­ione over the last decades. Hov­ione is a great com­pa­ny be­cause of its peo­ple and its clients. It has been an amaz­ing en­tre­pre­neur­ial and hu­man jour­ney with so many projects and un­for­get­table suc­cess sto­ries. I have seen this com­pa­ny, found­ed by my par­ents, grow­ing, evolv­ing and con­stant­ly re-in­vent­ing it­self,” Vil­lax said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.